HPTX Profile
Hyperion Therapeutics, Inc. (HPTX) was a biopharmaceutical company that focused on developing and commercializing therapies for rare and neglected diseases. The company was headquartered in Brisbane, California, and was founded in 2007.
Hyperion's primary product was Ravicti (glycerol phenylbutyrate), which was approved by the US Food and Drug Administration (FDA) in 2013 for the treatment of urea cycle disorders. Urea cycle disorders are a group of rare genetic disorders that prevent the body from properly breaking down ammonia, which can lead to serious health problems. Ravicti is an oral medication that helps to lower levels of ammonia in the blood by providing an alternative pathway for its elimination.
In 2015, Horizon Pharma plc (now Horizon Therapeutics plc) acquired Hyperion Therapeutics in a deal worth approximately $1.1 billion. As part of the acquisition, Horizon gained the rights to Ravicti as well as other pipeline products in development at Hyperion.
Following the acquisition, Hyperion Therapeutics was delisted from the NASDAQ stock exchange, and the company no longer exists as an independent entity.
|
